BioSpace News Archive

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $16.00 per share

Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of $9.50 per share.

OTX-2002 To Be Developed for the Treatment of MYC-Driven Hepatocellular Carcinoma Company is Advancing Candidate Into IND-Enabling Studies, with the Goal of Commencing a Phase 1/2 Clinical Trial Thereafter

Providence, one of the largest health systems in the country, announced that Rod Hochman, M.D., president and CEO, moved into his role as the American Hospital Association’s board chair for 2021.

Partnership to Accelerate Adoption of Next-Generation Sequencing (NGS) in Clinical Decision-Making Comprehensive Pan-Cancer Tumor Profiling Assays can be Combined with Clinical Informatics Platform with Potential to Reduce Time to Results and Complexity of Clinical Genomic Analysis

This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below

Interim DESTINY-Lung01 research data from the HER2 overexpressing metastatic non-small cell lung cancer (NSCLC) cohort of ENHERTU ® will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR

Caliber Ophthalmics, a Surgical Specialties Corporation company, is pleased to announce the opening of a state of the art ophthalmology design and manufacturing Center of Excellence in Sinking Spring, PA.

New research in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers.

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Graphite Bio, Inc., a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced a research and clinical collaboration agreement to evaluate JSP191, Jasper’s first-in-class anti-CD117 monoc